跳转至内容
Merck
CN

A4638

硫唑嘌呤

synthetic (organic), ≥98%, DNA/RNA synthesis disruptor, powder

别名:

6-[(1-甲基-4-硝基-1H-咪唑-5-基)硫代]-1H-嘌呤

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C9H7N7O2S
化学文摘社编号:
分子量:
277.26
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352202
EC Number:
207-175-4
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


产品名称

硫唑嘌呤, ≥98%

biological source

synthetic (organic)

Quality Level

assay

≥98%

form

powder

solubility

1 M NH4OH: 20 mg/mL, clear to slightly hazy

storage temp.

−20°C

SMILES string

Cn1cnc(c1Sc2ncnc3[nH]cnc23)[N+]([O-])=O

InChI

1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13)

InChI key

LMEKQMALGUDUQG-UHFFFAOYSA-N

Gene Information

human ... PPAT(5471)

Biochem/physiol Actions

在脱发性斑秃(自身免疫性脱发)的治疗中显示出希望,并在男女之间的疗效上无差异。


Still not finding the right product?

Explore all of our products under 硫唑嘌呤


wgk

WGK 3

pictograms

Health hazardExclamation mark

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Carc. 1B - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Susan Farshi et al.
International journal of dermatology, 49(10), 1188-1193 (2010-10-05)
Alopecia areata is an autoimmune disease resulting in partial or total nonscarring hair loss and the treatment of severe alopecia areata is difficult. The aim of this study was to evaluate the efficacy and safety of azathioprine as a systemic
Systemic therapies for severe atopic dermatitis in children and adults.
Carsten Flohr et al.
The Journal of allergy and clinical immunology, 132(3), 774-774 (2013-09-03)
Joanna Kitley et al.
Journal of neurology, neurosurgery, and psychiatry, 84(8), 918-921 (2013-03-08)
Neuromyelitis optica (NMO) is a severe autoimmune inflammatory disorder associated with considerable relapse-related disability. Immunosuppression is the mainstay of treatment but many patients do not tolerate first-line immunosuppressive agents, or experience ongoing relapses. To evaluate the effectiveness and tolerability of



全球贸易项目编号

货号GTIN
A4638-1G04061833374801